In vivo TargetModulation and Biological Activity of CHIR-258 , aMultitargeted Growth Factor Receptor Kinase Inhibitor , in Colon CancerModels
S. H. Lee,D. DeMenezes,JayeshVora,A. Harris,Helen Ye,Lara Nordahl,E. Garrett,E. Samara,S. L. Aukerman,A. Gelb,C. Heise
Abstract:Purpose:To evaluate the therapeutic and biological effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases, in colon cancer models. Experimental Design:The pharmacologic activity of CHIR-258 was characterized by monitoring target modulation as well as by evaluating the antitumor and antiangiogenic effects in human colon xenograft models. Results:CHIR-258 inhibits vascular endothelial growth factor receptor1/2, fibroblastgrowthfactor receptor1/3, and platelet-derived growth factor receptor B (PDGFRB) and shows both antitumor and antiangiogenic activities in vivo. Treatment of KM12L4a human colon cancer cells with CHIR-258 resulted in a dose-dependent inhibition of vascular endothelial growth factor receptor 1and PDGFRB phosphorylation and reduction of phosphorylated extracellular signal-regulated kinase (ERK) levels, indicating modulation of target receptors and downstream signaling. In vivo administration of CHIR-258 resulted in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm). Immunohistochemical analysis showed a reduction of phosphorylated PDGFRB and phosphorylated ERK in tumor cells after oral dosing with CHIR-258 compared with control tumors.These changes were accompanied by decreased tumor cell proliferation rate and reduced intratumoral microvessel density. CHIR-258 inhibited the phosphorylation of PDGFRB and ERK phosphorylation in tumors within 2 hours following dosing and the inhibitory activity was sustained for >24 hours. Significant antitumor activity was observedwith intermittent dosing schedules, indicating a sustained biological activity. Conclusion:These studies provide evidence that biological activity of CHIR-258 in tumors correlateswith efficacy andaids in the identificationof potential biomarkers of thismultitargeted receptor tyrosine kinase inhibitor. CHIR-258 exhibits properties that make it a promising candidate for clinical development in a variety of solid and hematologic malignancies. Cancer is the result of a multistep process of genomic alterations, including mutations in key regulatory proteins that result in loss of balanced gene expression and subsequent malignant transformation. Receptor tyrosine kinases (RTK) are mediators of cellular proliferation and mutations are often associated with hyperplasia and tumor development (1–3). These transmembrane RTKs contain an extracellular domain for ligand binding and intracellular kinase domains that mediate autophosphorylation, recruitment of downstream signaling molecules, and signal transduction. There are >30 RTKs implicated in cancer, including the type III [plateletderived growth factor receptor (PDGFR), colony-stimulating factor receptor, FMS-like tyrosine kinase 3, and KIT], type IV [fibroblast growth factor receptor (FGFR) 1-4], and type V [vascular endothelial growth factor receptor (VEGFR) 1-3] RTKs. RTK overexpression and/or activating mutations are often present in tumor cells and are implicated in tumor growth and progression of both solid and hematologic malignancies. For example, glioblastoma proliferation can be driven by overexpression of PDGFR, melanoma by VEGFR, and small cell lung cancer by KIT (4–9). In addition, a constitutively active mutation of KIT is associated with gastrointestinal stromal tumors (6, 10), and FMS-like tyrosine kinase 3 mutations are associated with disease progression in acute myelogenous leukemia (11, 12). Chromosomal translocations resulting in acquisition of PDGFR and FGFR activating mutations have been identified in chronic myelogenous monocyte leukemia and multiple myeloma, respectively (9, 13). In addition to their direct function in induction or maintenance of tumorigenesis, several RTKs, such as VEGFR, FGFR, and PDGFR, also play major roles in tumor angiogenesis, a process essential for growth of tumors (14, 15). In particular, VEGFR1-2 and FGFR1 on endothelial cells are activated by www.aacrjournals.org Clin Cancer Res 2005;11(10)May15, 2005 3633 Authors’Affiliations: Departments of Pharmacology, Translational Medicine, and Experimental Pathology, Pharmacokinetics and Drug Metabolism, and Applied Biochemistry, Chiron Corp., Emeryville, California Received10/18/04; revised 2/9/05; accepted 2/15/05. The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Requests for reprints: Carla Heise, Department of Translational Medicine, Chiron Corp., 4560 Horton Street, M/S 4.6, Emeryville, CA 94608. Phone: 510-9234036; Fax: 510-923-3360; E-mail: Carla___Heise@chiron.com. F2005 American Association for Cancer Research. Human Cancer Biology Research. on May 1, 2017. © 2005 American Association for Cancer clincancerres.aacrjournals.org Downloaded from VEGF or basic fibroblast growth factor secreted by tumor cells and stromal cells, resulting in proliferation, migration, and survival of tumor endothelial cells (3, 15–17). PDGFRh is expressed on pericytes, smooth muscle cells, and stromal cells and is involved in pericyte recruitment and vessel maturation during tumor angiogenesis and PDGF-BB is expressed in several stromal cell types (18–22). The increased understanding of the molecular pathways responsible for oncogenesis, angiogenesis, and tumor progression have led to the development of successful mechanismbased cancer therapies. Throughout the various stages of colon cancer, complex genetic alterations occur, of which overexpression of growth factors, such as VEGF, FGF, and PDGF and their corresponding RTKs, have been shown to correlate with invasiveness, tumor angiogenesis, metastasis, recurrence, and poor prognosis of colorectal cancer (23–27). Because colorectal cancer is the third most common cancer and third leading cause of death due to cancer in both men and women in the United States, a therapeutic agent that inhibits these RTKs has the potential to be a broadly effective therapy through both antitumor and antiangiogenic mechanisms. Such targeted agents are expected to be better tolerated than chemotherapeutic agents, because they affect characteristics often unique to the cancer cells and/or soluble factors associated with tumor survival. Several of these agents have been approved by the Food and Drug Administration (e.g., imatinib, trastuzumab, gefitinib, cetuximab, and bevacizumab) and many others are in clinical trials. Bevacizumab, a recombinant humanized monoclonal antibody to VEGF, which inhibits tumor angiogenesis, showed a significant increase in survival of patients with metastatic colorectal cancer when used in combination with standard chemotherapy compared with standard chemotherapy alone (28–30). Cetuximab, an antibody against the epidermal growth factor receptor, is marketed for treatment of patients with advanced, metastatic colorectal cancer. Several small molecule inhibitors that target multiple RTKs (SU5416, SU6668, SU11248, CP-547,632, and PTK-787/ZK222584) also have been shown to inhibit tumor growth and angiogenesis in preclinical models of colon cancers (31 – 35). PTK-787/ ZK222584, an inhibitor of VEGFR, is now in phase III trials for colorectal cancer. CHIR-258 is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Because CHIR-258 simultaneously targets RTKs expressed in tumor cells, stromal cells, endothelial cells, and pericytes, it is expected to exhibit antitumor efficacy by both direct and indirect mechanisms. In this report, we provide data characterizing the combined antiangiogenic and antitumor activity of CHIR-258 in murine human colon xenograft models. Inhibition of tumor cell proliferation and reduction of intratumoral microvessel density were observed after treatment with CHIR-258 in vivo. The pharmacologic activity of CHIR-258 was evaluated by monitoring the in vivo inhibition of its target RTKs and downstream signaling molecules in tumor tissues. Plasma exposures necessary for target modulation and antitumor efficacy were also determined. These data indicate that CHIR258 has potent antitumor and antiangiogenic activities that are associated with target modulation and biological activity in vivo , characteristics necessary for a potentially successful clinical therapy. Materials andMethods Chemical synthesis. CHIR-258 [4-amino-5-fluoro-3-[6-(4-methyl-1piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone], with a molecular weight of 392.4, was synthesized at Chiron Corp. (Emeryville, CA). Tumor cell lines. The human colon cancer cell lines used for these studies were KM12L4a and HCT116. KM12L4a cells were obtained from Dr. I. Fidler (M.D. Anderson Cancer Center, Houston, TX) and cultured in EMEM supplemented with 10% fetal bovine serum, 200 mmol/L L-glutamine, and 100 mmol/L sodium pyruvate (Life Technologies, Inc., Gaithersburg, MD). HCT116 cells were obtained from American Type Culture Collection (Bethesda, MD) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 2 mmol/L L-glutamine (Life Technologies). Reverse transcription-PCR evaluation indicated that KM12L4a human colon cancer cells express VEGFR1/2 and PDGFRh, and HCT116 cells were positive for VEGFR1, PDGFRh, and FGFR1. For studies of target modulation in vitro , KM12L4a human colon cells were cultured in 10% serum-containing medium and incubated with CHIR-258 for 3 hours. In vivo studies. Female nu/nu mice (6-8 weeks old, 18-22 g) were obtained from Charles River Laboratories (Wilmington, MA). Animals received sterile rodent chow and water ad libitum and were housed in a barrier facility in sterile filter-top cages with 12-hour light/dark cycles. All experiments were conducted in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International and in accordance with all